AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16798860 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel specimens with pellicle after 10-minute erosive challenge
Number of subjects: 0
Study 16798860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin specimens with pellicle
Number of subjects: 0
Study 16798860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pellicle)
Number of subjects: 0
Study 13129692 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 133
Study 13129692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 10958810 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 15 mg (RDA)
Number of subjects: 16
Study 8968481 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor exercise for about 5 hours on day 3
Number of subjects: 10
Study 8968481 — intervention group
Group type: COMPARATOR
Intervention: Control group (remained in rooms and went shopping)
Number of subjects: 10
Study 1457117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg IV up to 60 mg
Number of subjects: 80
Study 1457117 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 3 micrograms/kg IV up to 250 micrograms
Number of subjects: 80
Study 29940986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushrim-activated power-assisted wheelchair (PAPAW)
Number of subjects: 24
Study 29940986 — intervention group
Group type: COMPARATOR
Intervention: Regular handrim wheelchair (RHW)
Number of subjects: 24
Study 27769601 — intervention group
Group type: EXPERIMENTAL
Intervention: EVERA device
Number of subjects: 34
Study 27769601 — intervention group
Group type: COMPARATOR
Intervention: AESTES device
Number of subjects: 34
Study 27769601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 24942631 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic partial pleurectomy (VAT-PP)
Number of subjects: 196
Study 24942631 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 196
Study 23380743 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 23380743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0
Study 21243762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg, 3 times a week
Number of subjects: 188
Study 18954630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial synchronous biventricular pacing
Number of subjects: 40
Study 18954630 — intervention group
Group type: COMPARATOR
Intervention: Atrial inhibited pacing
Number of subjects: 40
Study 18954630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial synchronous right ventricular pacing
Number of subjects: 40
Study 15718044 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 0
Study 15718044 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 15718044 — intervention group
Group type: COMPARATOR
Intervention: Young adults controls
Number of subjects: 0
Study 15718044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) stimulation
Number of subjects: 0
Study 12953086 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (PT)
Number of subjects: 798
Study 12953086 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 798
Study 10853413 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 349
Study 10853413 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 349
Study 10853413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioxane treatment
Number of subjects: 349
Study 8898643 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/4 h)
Number of subjects: 161
Study 8898643 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (continuous infusion of 250 micrograms/h after an intravenous injection of 250 micrograms)
Number of subjects: 161
Study 8898643 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 161
Study 8898643 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 161
Study 1847706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan 100 mg
Number of subjects: 16
Study 1847706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan 30 mg
Number of subjects: 16
Study 1847706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6391877 — intervention group
Group type: COMPARATOR
Intervention: Traditional calorically defined exchange‐type diet (EXCH)
Number of subjects: 51
Study 6391877 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmeasured diet emphasizing avoidance of refined sugar and balance of food consumption throughout the day
Number of subjects: 51
Study 31303706 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (1 mcg/kg, max 75 mcg)
Number of subjects: 100
Study 31303706 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (0.1 mg/kg, max 8 mg)
Number of subjects: 100
Study 31303706 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 100
Study 31303706 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 100
Study 30267340 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearSight™ system (Edwards Lifesciences)
Number of subjects: 40
Study 30267340 — intervention group
Group type: COMPARATOR
Intervention: Control group (oscillometric blood pressure monitoring)
Number of subjects: 40
Study 26908434 — intervention group
Group type: EXPERIMENTAL
Intervention: JC seropositivity prior to diagnosis
Number of subjects: 342
Study 26908434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of JC seroreactivity
Number of subjects: 342
Study 26908434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of BK seroreactivity
Number of subjects: 342
Study 26908434 — intervention group
Group type: COMPARATOR
Intervention: BK and JC seroreactivity stability
Number of subjects: 342
Study 26908434 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion following SCC diagnosis
Number of subjects: 342
Study 24994839 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (low-dose)
Number of subjects: 4684
Study 24994839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4684
Study 22545823 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training program (formerly Battlemind training)
Number of subjects: 782
Study 21171982 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule of hepatitis B vaccine
Number of subjects: 234
Study 21171982 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule of hepatitis B vaccine
Number of subjects: 234
Study 21171982 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of hepatitis B vaccine
Number of subjects: 234
Study 16846342 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP + 1.0 mg/mL of recombinant human PDGF‐BB (rhPDGF‐BB)
Number of subjects: 16
Study 16846342 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP carrier alone
Number of subjects: 16
Study 16846342 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP + 0.3 mg/mL of rhPDGF‐BB
Number of subjects: 16
Study 12630351 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine B[symbol: see text]‐4 by intranasal‐subcutaneous method
Number of subjects: 54
Study 12630351 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycomponent vaccine B[symbol: see text]‐4 by intranasal oral method
Number of subjects: 54
Study 12630351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10853303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency Oriented Perimetry (TOP)
Number of subjects: 38
Study 10853303 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Doubling Perimetry (FDP)
Number of subjects: 38
Study 10853303 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma Diagnostic (GDx)
Number of subjects: 38
Study 9114644 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and developmentally sensitive family intervention program
Number of subjects: 0
Study 8251287 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinitroglycerin (TNG)
Number of subjects: 16
Study 8251287 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 16
Study 8251287 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinitroglycerin (TNG) and Isosorbide dinitrate (ISDN)
Number of subjects: 16
Study 2579938 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy split course
Number of subjects: 409
Study 2579938 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy continuous course
Number of subjects: 409
Study 2579938 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy continuous course
Number of subjects: 409
Study 2579938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan
Number of subjects: 409
Study 2579938 — intervention group
Group type: COMPARATOR
Intervention: No further therapy following irradiation
Number of subjects: 409
Study 31596961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 36472
Study 31596961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 36472
Study 31596961 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 36472
Study 31851348 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support with the Child Health Improvement Through Computer Automation system (CHICA) in intervention clinics.
Number of subjects: 274
Study 31851348 — intervention group
Group type: COMPARATOR
Intervention: Control clinics without the CHICA intervention.
Number of subjects: 274
Study 31851348 — intervention group
Group type: EXPERIMENTAL
Intervention: CHICA screening results.
Number of subjects: 274
Study 31851348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group.
Number of subjects: 274
Study 28335729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weeks of training with an oral screen for neuromuscular training focused on orofacial and pharyngeal muscles
Number of subjects: 400
Study 28335729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 25774595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model incorporating donor IL6 (rs1800797) and IFNG (rs2069727) genotypes and gastrointestinal involvement
Number of subjects: 268
Study 25774595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model predictive effect in validation set
Number of subjects: 268
Study 25774595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model association with response to therapy, overall and GVHD-specific survival and non-relapse mortality
Number of subjects: 268
Study 23547564 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 70
Study 23547564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22152644 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Psychiatric Rehabilitation (PR) Approach
Number of subjects: 156
Study 22152644 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 156
Study 19374150 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing thin liquids (milk, water, barium)
Number of subjects: 20
Study 19374150 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing various bolus types (5 or 10 mL)
Number of subjects: 20
Study 19374150 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy older adults swallowing thin liquids compared to puree or solids
Number of subjects: 20
Study 17988533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymatrine (600 mg, intravenous drip, once a day for 7 days)
Number of subjects: 418
Study 17988533 — intervention group
Group type: COMPARATOR
Intervention: Traditional equilibrium salt treatment (control group)
Number of subjects: 418
Study 15247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacred Heart Halo
Number of subjects: 6
Study 15247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sur-Catch NT
Number of subjects: 6
Study 15247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Halo
Number of subjects: 6
Study 15247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vantage
Number of subjects: 6
Study 15247730 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerotip
Number of subjects: 6
Study 12495801 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management condition 1
Number of subjects: 1063
Study 12495801 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management condition 2
Number of subjects: 1063
Study 12495801 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1063
Study 9400460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (10 ml)
Number of subjects: 40
Study 9400460 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 7645436 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume spacers (LVSs)
Number of subjects: 40
Study 7645436 — intervention group
Group type: COMPARATOR
Intervention: Metered-dose inhalers (MDIs)
Number of subjects: 40
Study 7645436 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 40
Study 2496075 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 7
Study 2496075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2496075 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 7
Study 138557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% betamethasone benzoate gel
Number of subjects: 121
Study 138557 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 121
Study 31364343 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical method (using sharp dissection)
Number of subjects: 45
Study 31364343 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 45
Study 31364343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cautery
Number of subjects: 45
Study 31364343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 28102456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab bimonthly (RABIMO group)
Number of subjects: 40
Study 28102456 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab PRN (PRN group)
Number of subjects: 40
Study 25647654 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal Interval Training (SMIT) - 10 × 30-second intervals at 150% of the peak power output (PPO) with 4-minute rest
Number of subjects: 20
Study 25647654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) - 8 × 2.5-minute intervals at 90% of the peak power output (PPO) with 3-minute rest
Number of subjects: 20
Study 22669627 — intervention group
Group type: EXPERIMENTAL
Intervention: Po-husk (14 g/day)
Number of subjects: 178
Study 22669627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose 14 g/day)
Number of subjects: 178
Study 21411833 — intervention group
Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 10
Study 21411833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 10
Study 19457565 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 268
Study 19457565 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 268
Study 16362803 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anal stimulation at 35 Hz
Number of subjects: 90
Study 16362803 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation at 1 Hz
Number of subjects: 90
Study 15130646 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lens (IOL) implantation with primary posterior continuous curvilinear capsulorhexis (PCCC) and anterior vitrectomy in Group 1 (n = 37)
Number of subjects: 72
Study 15130646 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with no PCCC in Group 2A (n = 37)
Number of subjects: 72
Study 15130646 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with PCCC and no vitrectomy in Group 2BN (n = 14)
Number of subjects: 72
Study 15130646 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL implantation with PCCC and vitrectomy in Group 2BV (n = 15)
Number of subjects: 72
Study 15130646 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for AcrySof IOL implantation
Number of subjects: 72
Study 11697018 — intervention group
Group type: EXPERIMENTAL
Intervention: LW 50020 (oral immunomodulator containing antigens of seven bacteria common in RTIs)
Number of subjects: 188
Study 11697018 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (immunization cycle + one booster cycle)
Number of subjects: 188
Study 11697018 — intervention group
Group type: COMPARATOR
Intervention: Two consecutive booster cycles
Number of subjects: 188
Study 11697018 — intervention group
Group type: EXPERIMENTAL
Intervention: LW 50020
Number of subjects: 188
Study 9131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 48
Study 9131882 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 48
Study 7910237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral compression ultrasound
Number of subjects: 100
Study 3293699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay rapid test
Number of subjects: 250
Study 3293699 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 250
Study 3293699 — intervention group
Group type: COMPARATOR
Intervention: Previous prescribing decisions
Number of subjects: 250
Study 31464152 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 0
Study 31464152 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 0
Study 31464152 — intervention group
Group type: COMPARATOR
Intervention: Deutetrabenazine 36 mg/day
Number of subjects: 0
Study 31464152 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 0
Study 28166613 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological agents (etanercept, infliximab, adalimumab)
Number of subjects: 129
Study 28166613 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs (methotrexate, cyclosporin)
Number of subjects: 129
Study 24705615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 602
Study 24705615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 22038536 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mg nicotine patch
Number of subjects: 28
Study 22038536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20334663 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 30
Study 20334663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (270 mg/day)
Number of subjects: 30
Study 20334663 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 30
Study 17645591 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise; supervised endurance exercise three times a week.
Number of subjects: 188
Study 17645591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise, dietary advice or no advice).
Number of subjects: 188
Study 16133653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight-bearing training program (50 min, twice a week)
Number of subjects: 48
Study 16133653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 12112165 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of white matter hyperintensities (WMH)
Number of subjects: 108
Study 12112165 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep white matter changes
Number of subjects: 108
Study 12112165 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular changes
Number of subjects: 108
Study 12112165 — intervention group
Group type: COMPARATOR
Intervention: Baseline reaction time and switch‐cost
Number of subjects: 108
Study 10089837 — intervention group
Group type: EXPERIMENTAL
Intervention: First shock at twice DFT plus, second to fifth shocks at maximum output (34 J)
Number of subjects: 166
Study 10089837 — intervention group
Group type: COMPARATOR
Intervention: All shocks programmed at 34 J
Number of subjects: 166
Study 11995907 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐and‐moisture‐retaining masks
Number of subjects: 10
Study 11995907 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 10
Study 2189613 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16
Study 2189613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7447618 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 26
Study 30975217 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 10 cmH2O with lung recruitment maneuvers (RM)
Number of subjects: 2378
Study 30975217 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 5 cmH2O without recruitment maneuvers (RM)
Number of subjects: 2378
Study 27884660 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10μg BID)
Number of subjects: 23
Study 27884660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26163609 — intervention group
Group type: COMPARATOR
Intervention: Tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid)
Number of subjects: 200
Study 26163609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored triple therapy plus pretreatment with probiotic containing yogurt
Number of subjects: 200
Study 23646471 — intervention group
Group type: EXPERIMENTAL
Intervention: Baidanhang lavage fluid nasal irrigation (BLFNI)
Number of subjects: 90
Study 23646471 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline with dexamethasone and gentamycin (Control)
Number of subjects: 90